1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 0,000 | 0,000 | 23.12. |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 10:37 | DiagnosTear Technologies: Zwei Durchstarter für 2026?! | bullVestor | |||
| 18.12. | DiagnosTear Technologies Inc.: DiagnosTear Signs Non-Binding Term Sheet with Sheba Impact and Ramot to Exclusively License New Eye Imaging Technology, CLARIFY, Enabling Needle-Free Blood Count | 478 | Newsfile | Vancouver, British Columbia--(Newsfile Corp. - December 17, 2025) - DiagnosTear Technologies Inc. (CSE: DTR) (FSE: X8F) ("DiagnosTear" or the "Company"), a leader in rapid eye based diagnostic technologies... ► Artikel lesen | |
| 15.12. | DiagnosTear: A diagnostic technology stock at the forefront of ocular disease | 3 | The Market Herald Canada | ||
| 10.12. | Diagnostear Technologies Inc: Diagnostear does not say why stock is up | 6 | Stockwatch | ||
| DIAGNOSTEAR TECHNOLOGIES Aktie jetzt für 0€ handeln | |||||
| 09.12. | DiagnosTear Technologies Inc. - Confirmation of No Material Change | 299 | Newsfile | Vancouver, British Columbia--(Newsfile Corp. - December 9, 2025) - DiagnosTear Technologies Inc. (CSE: DTR) (FSE: X8F) ("DiagnosTear" or the "Company"), a fast-growing innovator in point-of-care ocular... ► Artikel lesen | |
| 02.12. | DiagnosTear Technologies Inc.: DiagnosTear Announces Clinical Study with AlyaTec to Advance Analytical Validation and FDA Submission Pathway of TeaRx Red Eye Diagnostic Test | 334 | Newsfile | Vancouver, British Columbia--(Newsfile Corp. - December 2, 2025) - DiagnosTear Technologies Inc. (CSE: DTR) (FSE: X8F) ("DiagnosTear" or the "Company"), a fast-growing innovator in point-of-care ocular... ► Artikel lesen | |
| 27.11. | Diagnostear Technologies Inc: Diagnostear, LV Prasad enter partnership for TeaRx | 3 | Stockwatch | ||
| 26.11. | DiagnosTear Technologies Inc.: DiagnosTear Technologies Announces Initiation of a Collaboration with LV Prasad Eye Institute for Advancing the Clinical Validation of TeaRx Red Eye Diagnostic Test | 371 | Newsfile | Vancouver, British Columbia--(Newsfile Corp. - November 26, 2025) - DiagnosTear Technologies Inc. (CSE: DTR) ("DiagnosTear" or the "Company"), a leader in developing cutting-edge point-of-care eye... ► Artikel lesen | |
| 19.11. | Diagnostear Technologies Inc: Diagnostear Technologies closes $925,000 financing | 8 | Stockwatch | ||
| 18.11. | DiagnosTear Technologies Inc. Announces Closing of Private Placement of Units | 324 | Newsfile | Vancouver, British Columbia--(Newsfile Corp. - November 18, 2025) - DiagnosTear Technologies Inc. (CSE: DTR) (FSE: X8F) ("DiagnosTear" or the "Company") Further to its press release from June 3, 2025... ► Artikel lesen | |
| 24.10. | Diagnostear Technologies Inc: Diagnostear increases financing to $1-million | 1 | Stockwatch | ||
| 24.10. | DiagnosTear Technologies Inc. Announces Upsizing of Private Placement of Units | 355 | Newsfile | Vancouver, British Columbia--(Newsfile Corp. - October 24, 2025) - DiagnosTear Technologies Inc. (CSE: DTR) (FSE: X8F) ("DiagnosTear" or the "Company") is pleased to announce, further to its press... ► Artikel lesen | |
| 23.10. | Diagnostear Technologies Inc: Diagnostear begins trading on FSE, hires marketing firm | 3 | Stockwatch | ||
| 22.10. | DiagnosTear Technologies Inc.: DiagnosTear Announces Frankfurt Stock Exchange Listing and Corporate Awareness Agreement | 512 | Newsfile | Vancouver, British Columbia--(Newsfile Corp. - October 22, 2025) - DiagnosTear Technologies Inc. (CSE: DTR) (FSE: X8F) ("DiagnosTear" or the "Company") is pleased to announce that its common shares... ► Artikel lesen | |
| 17.09. | XFRA NEW INSTRUMENTS AVAILABLE ON 17.09.2025 | 565 | Xetra Newsboard | The following instruments on XETRA do have their first trading 17.09.2025 Die folgenden Instrumente in XETRA haben ihren ersten Handelstag 17.09.2025
Aktien
1 KYG4417G1064 Hesai Group
2 DE0005533400... ► Artikel lesen |
15 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| SIEMENS HEALTHINEERS | 44,500 | -0,54 % | JEFFERIES stuft Siemens Healthineers auf 'Buy' | NEW YORK (dpa-AFX Analyser) - Das Analysehaus Jefferies hat die Einstufung für Siemens Healthineers vor Zahlen zum ersten Geschäftsquartal auf "Buy" mit einem Kursziel von 60 Euro belassen. Der Medizintechnikkonzern... ► Artikel lesen | |
| INTUITIVE SURGICAL | 489,40 | -0,88 % | Is ISRG's 20% Procedure Growth the New Normal or a Peak? | ||
| THERMO FISHER | 491,15 | +1,76 % | Favorable Results and Improved Guidance Lifted Thermo Fisher Scientific (TMO) in Q3 | ||
| OTTOBOCK | 64,80 | -0,46 % | INDEX-MONITOR: Zahlreiche Wechsel in MDax und SDax - Dax unverändert | ZUG (dpa-AFX) - In der zweiten und dritten deutschen Börsenreihe gibt es zum Wochenstart zahlreiche Wechsel. In den MDax werden die Börsenneulinge Aumovio und TKMS aufgenommen, während Gerresheimer... ► Artikel lesen | |
| NETRAMARK | 0,675 | -3,57 % | NetraMark blickt auf ein transformatives Quartal mit wichtigen Erfolgen zurück | Anstieg des Auftragsbestands auf 2,5 Mio. CAD, Abschluss der CPIM-Gespräche mit der FDA, Annahme der Studie zur Veröffentlichung im Verlagsportfolio
von Nature, Onboarding eines wichtigen Vertriebspartners... ► Artikel lesen | |
| GETINGE | 19,520 | +0,31 % | Getinge Q3 Profit Surges; Confirms Annual Outlook | STOCKHOLM (dpa-AFX) - Getinge AB (GETI-B.ST), a medtech company, on Tuesday reported a profit before tax of SEK 789 million for the third quarter, a sharp increase from SEK 32 million in the... ► Artikel lesen | |
| DYNAVOX GROUP | 9,385 | +0,59 % | Dynavox Group AB: Dynavox Group to acquire SR Labs Healthcare in Italy | Dynavox Group AB (publ), the parent company of Tobii Dynavox and the global leader in assistive communication, has entered into an agreement to acquire all shares of its Italian reselling partner, SR... ► Artikel lesen | |
| LIFESTANCE HEALTH GROUP | 7,130 | +0,56 % | LifeStance Health Group, Inc.: LifeStance Reports Third Quarter 2025 Results | SCOTTSDALE, Ariz., Nov. 06, 2025 (GLOBE NEWSWIRE) -- LifeStance Health Group, Inc. (Nasdaq: LFST), one of the nation's largest providers of outpatient mental healthcare, today announced financial... ► Artikel lesen | |
| POSITRON | - | - | Positron Corporation Announces Its Transition to a Reporting SEC Company | Buffalo, NY, Nov. 17, 2025 (GLOBE NEWSWIRE) -- Positron Corporation ("Positron" or the "Company") (OTC: POSC), a leader in molecular imaging technology and services, today announced that it has become... ► Artikel lesen | |
| ALIGNMENT HEALTHCARE | 18,780 | -1,93 % | Alignment Healthcare, Inc. - S-8, Securities to be offered to employees in employee benefit plans | ||
| BRIGHTSPRING HEALTH SERVICES | 37,750 | +0,05 % | S&P Dow Jones Indices: BrightSpring Health Services Set to Join S&P SmallCap 600 | NEW YORK, Oct. 14, 2025 /PRNewswire/ -- BrightSpring Health Services Inc. (NASD: BTSG) will replace Veritex Holdings Inc. (NASD: VBTX) in the S&P SmallCap 600 effective... ► Artikel lesen | |
| NATERA | 233,64 | -0,81 % | Natera, Inc.: Natera and MEDSIR to Collaborate on the MiRaDoR Trial in Breast Cancer | Multicenter, Signatera Genome-guided interventional trial will evaluate different treatment approaches in HR+/HER2- breast cancer Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA... ► Artikel lesen | |
| PROGYNY | 25,800 | +1,14 % | Progyny, Inc. Announces Third Quarter 2025 Results | Reports Revenue of $313.3 Million, Reflecting 9.3% GrowthRaises Full Year Guidance to Reflect Continued Strength in Member EngagementSelling Season Yields Over 80 New Clients, 900,000 New Lives, and... ► Artikel lesen | |
| PROCEPT BIOROBOTICS | 32,410 | -1,43 % | Promising Growth Forecasts Leading to Analysts' Optimism for Procept Biorobotics (PRCT) | ||
| HEARTFLOW | 29,830 | -2,00 % | Heartflow, Inc.: Heartflow FFRCT Analysis Delivers Prognostic Power and Significant Cost Savings in New Analyses of Over 90,000 Patients with Coronary Artery Disease | Lesion-specific FFRCT predicts individual cardiovascular outcomes and delivers greater-than-modeled cost savings for real-world population in FISH&CHIPS analyses from England's National Health ServiceMOUNTAIN... ► Artikel lesen |
DIAGNOSTEAR TECHNOLOGIES INC gehört der Branche Gesundheitswesen an. Der aktuelle Kurs liegt bei 0,332 Euro und damit -4,60 % im Minus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu DIAGNOSTEAR TECHNOLOGIES INC finden Sie auf Wallstreet Online.